Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Designation symbols : Lly save search
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.65%
H: 0.49%
C: 0.07%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.35%
H: 2.21%
C: 1.9%
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: -0.33%
H: 2.55%
C: 1.4%
treatment designation china therapy study
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
ACIU | $2.43 0.41% 0.41% 370K
|
Health Technology
|
| O: 11.62%
H: 73.3%
C: 53.85%
aci-24 fda disease active alzheimer’s treat designation fast track designation
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published: 2023-06-02 (Crawled : 00:20) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
treatment designation therapy
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
Published: 2023-05-15 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.22%
H: 0.14%
C: -0.2%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.34%
H: 1.13%
C: 1.07%
ibi351 designation
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
Published: 2023-05-09 (Crawled : 12:00) - globenewswire.com
ACRV P | $10.56 2.13% 2.08% 370K
|
|
| O: 4.88%
H: 1.8%
C: 1.8%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.89%
C: -0.79%
acr-368 fda cancer designation grants therapeutics fast track designation
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation medical granted review china
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation drug medical application granted review china
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.59%
H: 0.15%
C: -0.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.63%
H: 2.86%
C: 2.01%
ibi351 designation lung therapy cancer
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
Published: 2022-10-06 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.16%
H: 3.45%
C: 1.53%
treatment fda designation fast track designation obesity tirzepatide
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 01:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-20 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.27%
H: 0.22%
C: -1.55%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 2.32%
H: 1.21%
C: 0.99%
treatment designation pharma drug application granted review china
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 17:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
Published: 2022-04-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -0.62%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.52%
H: 1.58%
C: 0.22%
ibi310 treatment cancer designation antibody
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.61%
H: 0.29%
C: -5.25%
fda heart therapy breakthrough therapy granted grant designation
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Published: 2021-06-24 (Crawled : 11:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 8.21%
H: 1.89%
C: -0.83%
disease alzheimer treatment fda therapy breakthrough therapy alzheimer’s alzheimer's disease alzheimer's designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.